Read how a long-term academic–industry neuroscience alliance is renewing multi-year commitments to advance neurodegenerative drug discovery and translational pipelines.
Key Takeaways
- UCL and Eisai extended their neuroscience alliance for five years through 2030
- They have invested about $13.6 million across eight drug discovery projects since 2012
- Therapy originating from the partnership is now in two Phase II clinical trials